With a market cap of $68.4 billion, Colgate-Palmolive Company (CL) is a global consumer staples company known for its strong leadership in oral care and a broad portfolio of everyday products across personal care, home care, and pet nutrition. The New York-based company is present in over 200 countries, and the company benefits from high brand loyalty, steady demand, and strong cash flows, making it a defensive player in the market.
The company is expected to announce its fiscal Q1 2026 results before the market opens on Friday, Apr. 24. Ahead of this event, analysts forecast Colgate-Palmolive to post an adjusted EPS of $0.95, up 4.4% from $0.91 in the year-ago quarter. It has exceeded Wall Street's earnings estimates in the last four quarters, which is admirable.
For fiscal 2026, analysts project the company to report an adjusted EPS of $3.89, a rise of 5.4% from $3.69 in fiscal 2025. Moreover, adjusted EPS is expected to grow 6.7% year over year to $4.15 in fiscal 2027.
Shares of Colgate-Palmolive have declined 9% over the past 52 weeks, lagging behind both the S&P 500 Index's ($SPX) 16.7% return and the State Street Consumer Staples Select Sector SPDR ETF’s (XLP) marginal dip over the same period.
Colgate-Palmolive Company shares fell over 2% on Mar. 31 after TD Cowen downgraded the stock from “Buy” to “Hold,” signaling a more cautious outlook.
Analysts' consensus view on CL stock is cautiously optimistic, with a "Moderate Buy" rating overall. Among 21 analysts covering the stock, nine recommend "Strong Buy," three "Moderate Buys," eight suggest "Hold," and one has a "Strong Sell." The average analyst price target for Colgate-Palmolive is $96.42, indicating a potential upside of 12.9% from the current levels
